Cancer Cure? OX40 TLR9
The recent research using OX40 intratumoral injections and TLR9 cured most mice of various types studied. This is a highly promising approach. The many clinical trials with OX40 now underway are systemically dosing which might not be as effective as an intratumroal dose. However, a new trial is now starting that will use the protocol used in the mice.
This is very exciting! I wish that through the power of social media that the truth about this treatment can be known as soon as possible. It could take many years for this knowledge to be gained if the usual clinical trial process were to be used. In fact the below clinical trial is expected to enroll 15 patients over the next 2 years. We can't wait! We want our lives to live again NOW! Life should be more than misery.
Jcancom, very good idea to open a new topic, since this treatment deserves its own space in the forum. I can imagine that Head Neck, Skin cancers, Lymphoma, Peritoneal Cancers can be addressed by this treatment very easily. Due to the fact the tumor is artificial.
So I really hope, other companies will open similar trails for other cancers as well.
But maybe it is not a magic bullet. Bromopyruvate cured also nearly all cancers in mice...
Apparently, people did not comply with your wish to move the conversation to here but I do. You are right on, monoclonal antibodies and a lot of immune based therapies are dangerous, cause autoimmune disease, shut down the kidneys, etc. All the more exciting that this ox40/tlr9 ligand combo is safe and less taxing for the immune system.
Regarding sponsoring by the PI, I doubt he sponsors it from his pocket, more probably from his grant. As you are so enthusiastic and have a high energy to get things done, and seem to be in the US, how about helping this guy with crowd funding?
At the same time, we could also set up a page for Daniel to support this research of his. His articles are immensely informative and more in-depth than anybody else's with practically a layperson's approach but with amazing knowledge and care.
If anybody knows how to proceed about crowd-funding, please respond!
Dr. Williams tweeted this https://twitter.com/jasonwilliamsmd/status/967073457371598849
Idera Pharma are running a basket trial (NCT03052205) using their TLR9 agonist (IMO-2125) and have treated patients with deep-seated tumours.
In Cohort 1 (8 mg per injection) eleven have been dosed and all completed the 21 day dose limiting toxicities period. No DLTs or other safety concerns have occurred. The types of cancers treated are: pancreatic (n=6), ocular melanoma (n=1), colorectal (n=1), chondrosarcoma (n=1), breast (n=1) and esophageal (n=1). Eight of these had their liver lesions injected. Now Cohort 2 (16 mg per injection) is enrolling.
Three patients in Cohort 1 continue to be treated and investigator assessments indicate stable disease in two (pancreatic & colorectal) under RECIST and another has stable disease (pancreatic) under irRECIST http://www.irrecist.com/
Dr. Jason Williams already incorporates in its crioablation protocol of the TLR9 agonist and anti OX40
The only TLR 7/8 agonist that's in a PhI is MEDI9197 http://cancerres.aacrjournals.org/.../77/13_Supplement/CT091 Based on preclinical data it could be combine with either SD-101 or IMO-2125 (TLR 9 agonists) https://jitc.biomedcentral.com/art.../10.1186/2051-1426-2-12 Nektar plan to test NKTR-262 plus NKTR-214 in the next few months http://www.nektar.com/.../NKTR-262-NKTR-214__2017SITC... Some of these drugs could be available via right-to-try.
The PhI/II of NKTR-262 will be open soon https://clinicaltrials.gov/ct2/show/NCT03435640 Initial data will be presented in the second half and I assume (rightly or wrongly) at a conference (SITC/ESMO).
Idera's TLR9 (IMO-2125) is now in a PhIII https://clinicaltrials.gov/ct2/show/NCT03445533 and SD-101 by Dynavax should be by the end of this year. It will be tested in newly diagnosed advanced melanoma patients in combo with Pembrolizumab (anti-PD1). The TLR4 agonist (G100) by Immune Design could be as well. Assuming the FDA grant this then they will be targeting relapsed/refractory (post anti-CD20) follicular NHL.